Supplementary 4: Tofacitinib outcomes

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Tofacitinib | | | | | | | | | | |
| Indication | Birth Outcomes | | | | | Congenital Malformation | Exposure Until | | | |
| Indication | Live Birth | Spontaneous Abortion | Still Birth | Ectopic Pregnancy | Elective Termination | Congenital Malformation | First | Second | Third | Ongoing |
| RA | 43 | 17 | 0 | 0 | 10 | 3 | 95 | 1 | 1 | 0 |
|  | 61.4% | 24.3% | 0.0% | 0.0% | 14.3% | 7.0% | 97.9% | 1.0% | 1.0% | 0.0% |
| PsA | 3 | 0 | 0 | 0 | 2 | 0 | 4 | 0 | 0 | 1 |
|  | 60.0% | 0.0% | 0.0% | 0.0% | 40.0% | 0.0% | 80.0% | 0.0% | 0.0% | 20.0% |
| PsO | 19 | 1 | 0 | 0 | 10 | 0 | 36 | 0 | 0 | 0 |
|  | 63.3% | 3.3% | 0.0% | 0.0% | 33.3% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% |
| UC | 13 | 2 | 0 | 0 | 2 | 0 | 17 | 0 | 0 | 2 |
|  | 76.5% | 11.8% | 0.0% | 0.0% | 11.8% | 0.0% | 89.5% | 0.0% | 0.0% | 10.5% |
| CD | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
|  | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 50.0% | 50.0% | 0.0% | 0.0% | 50.0% |
| SAPHO | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
|  | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | 0.0% |
| NR | 1 | 0 | 0 | 0 | 0 | 0 | NR | NR | NR | NR |
|  | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total | 82 | 20 | 0 | 0 | 24 | 4 | 154 | 1 | 1 | 4 |
| 126 | 65.1% | 15.9% | 0.0% | 0.0% | 19.0% | 4.9% | 96.3% | 0.6% | 0.6% | 2.5% |